Opening New Frontiers By Advancing The Promise of PI Signaling Pathways

Paul Sekhri 

Select a team to find out more

Paul Sekhri 

Paul Sekhri 

Chairman of the Board, Petra Pharma, President and Chief Executive Officer, eGenesis

With more than 25 years of experience in the life sciences industry, Paul Sekhri has held executive leadership positions at some of the world’s most widely-regarded pharmaceutical companies.  He currently serves as President and CEO of eGenesis, a biotechnology company focused on xenotransplantation.

Before arriving at eGenesis, Paul served as President and CEO of Lycera Corp., an innovative biopharmaceutical company focused on treatments for autoimmune diseases and cancer.  He served as Operating Partner at Highline Therapeutics, a biotech incubator launched by Versant Ventures, and earlier as Senior Vice President of Integrated Care at Sanofi S.A. where he led the creation of innovative solutions and business models to meet patient needs.  Before Sanofi, Paul led global business development and was Chief Strategy Officer at Teva Pharmaceuticals Industries, Ltd.  He also served as Operating Partner and head of the biotech ops group at TPG Biotech, the life sciences venture arm of the global private investment firm TPG, where he was responsible for a portfolio of more than 50 life sciences companies.

In 2014, Paul founded Cerimon Pharmaceuticals, Inc. and served as President and Chief Executive Officer until 2009.  He served as President and Chief Business Officer of ARIAD Pharmaceuticals, Inc., and a partner for healthcare investments at New Leaf Ventures.  Paul spent four years at Novartis AG in various senior positions, including Senior Vice President, Head of Global Search and Evaluation, Business Development and Licensing and Global Head of Early Commercial Development, where he developed the company’s disease area strategy and founded the early commercial development department.

Paul has served as a director on the Boards of Director for more than 24 private and public companies, a list that currently includes Ipsen Group, Compugen, Ltd., Alpine Immune Sciences, Inc., Pharming N.V., Topas Therapeutics GmbH and Petra Pharma Corp.

Paul completed post-graduate studies in clinical anatomy and neurosciences at the University of Maryland, School of Medicine and received a B.S. in zoology from the University of Maryland College Park.